Opioid Use Disorder Resources for Practitioners

Practitioners play a crucial role in helping individuals with opioid use disorder (OUD) by providing comprehensive care, support, and access to evidence-based treatments. Here are some useful resources for practitioners working with individuals with opioid use disorder (OUD).

Websites

Nevada Recovery Friendly Workplace

In an effort to improve Nevada’s workplaces, the State of Nevada has developed a Recovery-Friendly Workplace Program to reduce the stigma of substance use and encourage workplaces to support treatment and recovery. Through education, and policy and procedure development to support recovery in all aspects, the program provides free resources to become a designated recovery-friendly workplace.

988 Suicide & Crisis Lifeline – Call. Text. Chat.

The 988 Lifeline provides 24/7, free and confidential support for people in distress, prevention and crisis resources for you or your loved ones, and best practices for professionals in the United States.

Talk To Someone Now | Help Yourself | Help Someone Else

Nevada Zero Suicide

The Zero Suicide framework is a system-wide, organizational commitment to safer suicide care in health and behavioral health care systems. The framework is based on the realization that suicidal individuals often fall through the cracks in a sometimes fragmented and distracted health care system. A systematic approach to quality improvement in these settings is both available and necessary.

Nevada Overdose Data to Action Program

The Overdose Data to Action Program (OD2A) supports the state in getting high quality, comprehensive and timelier data on opioid prescribing and mortality, and to use those data to inform the state’s prevention and interventions efforts. The Nevada OD2A Program is being administered by the Division of Public and Behavioral Health and involves partnerships that include the Nevada Board of Pharmacy, Washoe County Human Services, Washoe County Medical Examiner, Southern Nevada Health District, Family Support Center, and the Larson Institute at the University of Nevada, Reno School of Public Health.

Behavioral Health Nevada

This website is a database of behavioral health providers specializing in substance use disorder and co-occurring mental health disorder treatment services.  All agencies listed are Certified by the Division, SAPTA (Substance Abuse Prevention and Treatment Agency).

State Opioid Treatment Program Regulations

A PEW analysis of all state opioid treatment program regulations and how they support or limit access to care and impact patient experience.

Tools & Resources

A list and map of Fentanyl Test Strip Distribution Sites in Nevada.

SBIRT is a comprehensive, integrated, public health approach to delivering early intervention for individuals with risky alcohol & drug use. SBIRT provides a timely referral to more intensive substance use treatment for those with substance use disorders. Primary care centers, ERs, trauma centers, and community health settings provide opportunities for early intervention with at-risk substance users before more severe consequences occur. Adopt SBIRT serves Nevada with expertise and key resources to assist organizations to promote, prepare, adopt, and implement SBIRT.

This comprehensive guide provides information and recommendations regarding general health, safer use practices, common viral, fungal, parasitic, and other injection-related infections, overdose and overamp, tapering, withdrawal, medications for opioid use disorder, and seeking medical care.

Peer support services (PSS) are a valuable component of a growing number of overdose response and linkage to care initiatives that can be implemented and supported by local and state health departments. This toolkit is for local and state health departments and community partners who are exploring opportunities to implement or enhance PSS within overdose response and linkage to care initiatives. This toolkit provides information, resources, tools, actionable steps and real-world examples informed by the latest research, subject matter experts and experiences from diverse settings across the country.

To help public health practitioners prevent overdose, the National Council for Mental Wellbeing, in partnership with the Centers for Disease Control and Prevention, developed these resources and tools for overdose prevention.

There are a number of screening tools available that can be self-administered via pen and paper, computer and tablet, or conducted by an interviewer. Each screening tool has pros and cons and a program should decide which screening tool is best for their agency based on population served with consideration to which substances are being used as well as state/regional billable terms for utilization of specific screening forms. Adopt SBIRT offers training and technical assistance on the use of screening assessments.

A Nevada provider’s guide to prescribing Naloxone to patients who use opioids.

This guide was drawn from HEALing Communities Study (HCS) learnings to-date and expert insights to provide guidance regarding implementation of ORCCA menu strategies.

Includes graphs and tables on death rates, opioid-related emergency department visits and inpatient admissions, and opioid prescriptions at the county-level and zip code-level.

A dashboard to look at overdose death data for 2020 by substance for 29 states/jurisdictions.

A dashboard to look at emergency department non-fatal overdose data since February 2018 for all drugs, all opioids, heroin, or all stimulants by state.

This toolkit is a resource for Peer Recovery Specialists (PRSs) to feel equipped to discuss MOUD with providers, people seeking recovery, and others with questions about this treatment option.

This toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. The toolkit also emphasizes that harm reduction and access to treatment are essential aspects of overdose prevention.

Improper prescription drug use is a serious public health issue. Storing and disposing of medications properly can help reduce harm.

Publications

Johns Hopkins Medicine. (2024). Reducing the Stigma of Addiction. [Webpage]. Retrieved from [https://www.hopkinsmedicine.org/stigma-of-addiction]

This resource is the first to provide evidence-based information and strategies for APRNs and PAs who work with individuals with substance use disorders (SUDs). Written in a concise, bulleted style for easy access to critical information, the reference addresses often-undiagnosed medical and psychiatric conditions which may accompany SUDs and the ethical considerations of working with affected patients and families.

This document provides information on xylazine, a non-opioid veterinary tranquilizer used as an additive in illicit drug supplies, notably in combination with heroin and fentanyl. It discusses the effects of xylazine use, including sedation and potential risks such as hypotension and bradycardia. The document also emphasizes harm reduction interventions for individuals who may encounter xylazine in the drug supply, including the use of naloxone for responding to overdoses and the importance of wound identification and treatment.

This “Dear Colleague” letter from the Substance Abuse and Mental Health Services Administration (SAMHSA) provides a report on the risks of Xylazine.

The Society of Maternal–Fetal Medicine endorses this document. This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice in collaboration with committee members Maria A. Mascola, MD, MPH; Ann E. Borders, MD, MSc, MPH; and the American Society of Addiction Medicine member Mishka Terplan, MD, MPH.

Foote, Jeffrey. (2014). Beyond addiction : how science and kindness help people change : a guide for families. New York, NY :Scribner

The most innovative leaders in progressive addiction treatment in the US offer a groundbreaking, science-based guide to helping loved ones overcome addiction problems and compulsive behaviors.

Dydyk AM, Jain NK, Gupta M. Opioid Use Disorder. [Updated 2024 Jan]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan.

This activity focuses on the critical evaluation and management of opioid use disorder (OUD), a pervasive condition significantly diminishing patients’ quality of life and contributing to a widespread epidemic in the United States.

There are strategies that can assist community leaders, local and regional organizers, non-profit groups, law enforcement, public health, and members of the public in understanding and navigating effective ways to prevent opioid overdose in their communities. Use this information as a reference for evidence-based practices that have been successfully implemented in the U.S.

The Nevada State Targeted Response to the Opioid Crisis Strategic Plan was submitted to SAMHSA on December 21, 2018. The details of the plan can be found in the following document.

The purpose of this needs assessment is to identify the opioid use disorder (OUD) crisis in Nevada related to:

  • The geographical and demographic areas where opioid misuse and related harms are most prevalent;
  • All existing activities and funding sources in the state/jurisdiction that address opioid use prevention, treatment and recovery activities; and
  • Gaps in the existing services and resources to be addressed.

The needs assessment will inform decision making on how to best address the opioid crisis. The details of the needs assessment can be found in the following document.

In February 2018, a total of 1,074 healthcare providers responded to a needs assessment designed to guide development of opioid-related trainings to facilitate successful implementation of Nevada’s Opioid State Targeted Response.

This report provides an update on the present state of coverage, availability of, and access to, medications for treating ongoing alcohol use disorder (AUD) and opioid use disorder (OUD) and reversing an opioid overdose within state Medicaid plans. It also includes examples of innovative efforts to increase access to medications for the treatment of SUDs.

The Division of Health Care Financing and Policy has taken action to address the opioid crisis by updating Nevada Medicaid policy and opening Medication-Assisted Treatment (MAT)-related evaluation and management (E/M) codes for billing by Nevada Medicaid providers effective with dates of service on or after January 1, 2020. In addition to MAT related E/M codes, Nevada Medicaid opened Screening, Brief Intervention, Referral to Treatment (SBIRT) codes to assist providers in performing screening services to recipients at risk or struggling with Substance Use Disorder (SUD).

This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder

The Addiction Technology Transfer Center (ATTC) Network Coordinating Office (NCO), funded by the Substance Abuse and Mental Health Services (SAMHSA), has designed three competency-based guides to raise awareness of resources available to build the capacity of the workforce to address the opioid crisis. The digital guides are relevant to psychologists, counselors, social workers, peer support workers, and other behavioral health professionals who intersect with people at risk for misuse of, or who are already misusing, opioids.

A compilation of essays by individuals supported by Medication-Assisted Treatment in long-term recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD.

Posters & Infographics

Prescribe 365 Prescribing in Nevada Pocket Card

Prescribe 365 Prescribing in Nevada Pocket Card

Download the Pocket Card
Opioid Trifold Brochures

Opioid Trifold Brochures

Opioid Information Brochures for Providers or Consumers help educate on opioids and opioid use, including effects of opioid use, pregnancy and opioid use, medications for opioid use including opioid overdose reversal medications, and treatment options for persons using opioids.
Download or request free hard copies
Stimulant Trifold Brochures

Stimulant Trifold Brochures

Stimulant Information Brochures for Providers or Consumers help educate on stimulants, including the effects of stimulants use, pregnancy and stimulant use, and treatment options for persons using stimulants.
Download or request free hard copies
FACT SHEET Xylazine Clinical Management and Harm Reduction Strategies for Patients Xylazine, also called “tranq” or “tranq dope,” is a nonopioid sedative and tranquilizer. Xylazine has been increasingly found in the illegal drug supply in the United States and has been involved in overdose deaths.1 Although not a controlled substance, xylazine is not approved for use in humans and can be life threatening, especially when combined with opioids like fentanyl.2 The White House’s Office of National Drug Control Policy has declared fentanyl mixed with xylazine to be an emerging threat.3 Adverse Effects Xylazine-involved overdose symptoms include the following: • Central nervous system (CNS) depression • Respiratory depression • Bradycardia • Hypotension • Constricted pupils • Hyperglycemia Exposure • Xylazine is often mixed with illegal drugs like cocaine, heroin, and fentanyl, either to enhance effects or increase the drugs’ weight (which increases their illegal value).4,5 • People who use illegal drugs may not be aware that their drugs contain xylazine. Growing Role in Overdose Deaths • In drugs tested in labs, the presence of xylazine increased in every region of the United States from 2020-2021, with the most significant increase in the South.6 • In a recent CDC study spanning 20 states and Washington D.C., the monthly percentage of deaths involving illegally made fentanyl (IMF) with xylazine increased from 3% in January 2019 to 11% in June 2022. • Additionally, from January 2021 through June 2022, xylazine was found in a higher percentage of IMFinvolved deaths in the Northeastern U.S. than in other regions.7 Centers for Disease Control and Prevention National Center for Injury Prevention and Control www.cdc.gov/opioids

Xylazine: Clinical Management and Harm Reduction Strategies for Patients

This fact sheet is intended to guide healthcare professionals on the clinical management of Xylazine use and harm reduction strategies for their patients.
Download the fact sheet
Take Action to Prevent Addiction Learn how to reduce risk. Know the Facts About Opioids Talk With Your Doctor Your doctor may talk to you about prescription opioids for pain treatment. Ask about the risks and benefits so that you can work together to decide what is best. You can also ask your doctor to help you find other safer ways to manage pain. Every day in the United States, 41 people lose their lives to prescription opioid overdose. Prescription opioids—like hydrocodone, oxycodone, and morphine—can be prescribed by doctors to treat moderate to severe pain but can have serious risks and side effects. PEOPLE DIE 41EVERY DAY Opioids are highly addictive. Research shows that if you use opioids regularly, you may become dependent on them. That’s because opioids change how the brain and nervous system function. You can’t know how your brain will react to opioids before taking them. ANYONE CAN BECOME ADDICTED It Only Takes a Little to Lose a Lot Opioids affect the part of the brain that controls breathing. If you take too high a dose, it can slow your breathing and cause death. Opioids can be addictive and dangerous. Risks include misuse, addiction, and overdose. Combining opioids with alcohol and other drugs— like sleeping pills or cough medication —increases your chances of death.1 1 fda.gov/Drugs/DrugSafety/ucm518473.htm For those who might have an opioid use disorder, call SAMHSA’s National Helpline at 1-800-662-HELP. Start the Conversation Protect yourself and others by talking about your questions and concerns. Ask about nonopioid pain management options, addiction, and overdose risks. Talk with your doctor. Let them know that you care about them, and be patient and open when listening so that they feel heard and valued. Talk with your loved ones if you’re concerned about opioid misuse or addiction. Encourage your loved ones to get help if they need it. Help them look for treatment, and offer to go with them to their first appointment. Your support can make a difference. Treatment Support Learn the signs of a quality treatment center at goo.gl/X1FCGW. Find opioid treatment options in your state at goo.gl/Gtkv9C. Follow these tips to protect yourself and those you care about. Tips to Reduce Risk Only take prescription medication that is prescribed to you. Don’t share medication with others. Take the medicine as prescribed. Don’t use medications in greater amounts, more often, or longer than directed by your doctor. Keep medicines in a safe place. It’s best to store prescription opioids in a place that can be locked—like a keyed medicine cabinet—to keep them secure from children and visitors. Dispose of expired or unused prescription opioids. Remove them from your home as soon as possible to reduce the chance that others will misuse them. To get rid of prescription opioids and other medications safely: • Check with your pharmacist to see if you can return them to the pharmacy. • Find a medicine take-back option near you at takebackday.dea.gov. Hear real stories about recovery from prescription opioids at cdc.gov/RxAwareness.

Prevent Addiction Fact Sheet

This face sheet contains information for patients about preventing opioid addiction.
Download the fact sheet.
What You Need to Know About Treatment and Recovery There is hope. Recovery is possible. Addiction Is A Disease Opioids are highly addictive, and they change how the brain works. Anyone can become addicted, even when opioids are prescribed by a doctor and taken as directed. In fact, millions of people in the United States suffer from opioid addiction. Signs of Opioid Addiction A major warning sign of addiction is if a person keeps using opioids even though taking them has caused problems—like trouble keeping a job, relationship turmoil, or run-ins with law enforcement. Other signs can include:1 Opioid Use Disorder Sometimes referred to as “opioid addiction,” opioid use disorder is a chronic and relapsing disease that affects the body and brain. It can cause difficulties with tasks at work, school, or home, and can affect someone’s ability to maintain healthy relationships. It can even lead to overdose and death. Trying to stop or cut down on drug use, but not being able to. Taking one drug to get over the effects of another. Using drugs because of being angry or upset with other people. Being scared at the thought of running out of drugs. Stealing drugs or money to pay for drugs. Overdosing on drugs. To learn more about opioid misuse, go to cdc.gov/RxAwareness. 1 findtreatment.gov/content /understanding-addiction/addiction-can-affect-anyone Recovery Is Possible Recovery does not happen overnight. Asking for help from family, friends, co-workers, and others can make a big difference. Tell them your reasons for quitting and ask them to check in with you about how things are going. If you know or suspect someone is struggling, ask if you can help. Treatment Can Help Treatment can help people get their lives back before it is too late. No single treatment method is right for everyone, but research shows that combining behavioral therapy with medication is the most effective approach for overcoming opioid addiction. Addiction is a disease that for many involves long-term follow-up and repeated care to be effective and prevent relapse. When people make a recovery plan that includes medication for opioid use disorder, their chances of success increase. Medications can help normalize brain chemistry, relieve cravings, and in some cases prevent withdrawal symptoms. Medication-Assisted Treatment Options Talk with your doctor to find out what types of medication are available in your area and what options are best for you. Be sure to ask about the risk of relapse and overdose. Behavioral Health Treatment Services Locator: findtreatment.samhsa.gov Opioid Treatment Program Directory by State: dpt2.samhsa.gov/treatment/ directory.aspx Health Center Locator: findahealthcenter.hrsa.gov Mental Health and Addiction Insurance Help: hhs.gov/programs/topic-sites/ mental-health-parity/mentalhealth-and-addiction-insurancehelp/index.html Find Treatment Services Use these resources to find services that fit your needs: Methadone • Available as daily liquid • Can only be used in a certified opioid treatment program setting Buprenorphine • Available as dissolving tablet, cheek film, or 6-month implant under the skin • Can be prescribed by a doctor for use outside of a clinic Naltrexone • Can be prescribed by any healthcare provider who can legally prescribe medication • Only used for people who have not used opioids for at least 7–10 days Additional resources to access help: • Medication-Assisted Treatment (MAT) • Decisions in Recovery: Treatment for Opioid Use Disorder • Facing Addiction in America | The Surgeon General’s Report on Alcohol, Drugs, and Health

Opioid Use Disorder Treatment and Recovery Fact Sheet

This fact sheet contains important information about treatment and recovery of opioid use disorder for patients, families and friends.
Download the fact sheet

Webinars & Online Learning

Connecting university-based faculty specialists to primary care providers in rural and under-served areas.

Pain Management ECHO

Learn how to assess and manage your patients with pain through a variety of non-pharmacologic and pharmacologic modalities, as well as best practice approaches to minimizing the risk of addiction. This clinic is a forum guided by a Pain Management Physician, a Pain Management Psychologist, and a Mental Health and Addiction Specialist.

SBIRT for Health Professionals ECHO

The SBIRT for Health Professionals ECHO will provide community health professionals with the training and support they need to manage substance use issues within health settings specializing in treating pregnant and non-pregnant persons of reproductive age populations using an SBIRT model.

In this recorded webinar, panelists provide a brief overview of Xylazine, a substance newly found in illicit drug supplies, and its impacts on the unsheltered community. Panelists will share their lived expertise with xylazine, its effects, organizational best practices for wound care, overdose response, and harm reduction. 

To support linkage to care efforts for people at risk of overdose, the National Council for Mental Wellbeing, with support from the Centers for Disease Control and Prevention (CDC), developed Overdose Response and Linkage to Care: A Roadmap for Health Departments, a technical assistance tool informed by real-world experience. Attendees of this webinar will hear directly from health department staff implementing a variety of these linkage to care strategies to prevent overdose. These strategies can be adapted and replicated to meet the needs of communities across the country.

This Training is designed to educate mandated reporters on opioid misuse and abuse and how to report to Nevada Adult Protective Services if you suspect abuse of vulnerable adults. 

Current News & Research

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

WASHINGTON – The U.S. Drug Enforcement Administration is warning the American public of a sharp increase in the trafficking of fentanyl mixed with xylazine. Xylazine, also known as “Tranq,” is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use.  

Southern Nevada Health District calls attention to xylazine risk

The Southern Nevada Health District (SNHD) is urging heightened public awareness of the health dangers associated with xylazine, an animal tranquilizer that is increasingly being found in the country’s illicit drug supply and linked to overdose deaths throughout the United States. Xylazine, also known as “tranq,” is not approved for human consumption. It can be life-threatening and is especially dangerous when combined with opioids such as fentanyl.

Opioid Use Disorder Assessment Tools and Drug Screening

Ducharme J, Moore S. Opioid Use Disorder Assessment Tools and Drug Screening. Mo Med. 2019 Jul-Aug;116(4):318-324. PMID: 31527982; PMCID: PMC6699803.

Opioid use disorder risk assessment tools cannot be used in isolation. In combination with standardized clinical examination, and, when indicated, urine drug screening, a validated risk assessment tool, improves the ability to detect opioid misuse. Even though no single tool has been shown to have both high interobserver reliability and high sensitivity, the standardized approach has still been shown to be superior to subjective care giver assessment. This article will provide a global approach to risk assessment in addition to reviewing the available tools.

The Opioid Epidemic’s Toll on Children

This article from the Johns Hopkins Bloomberg School of Public Health discusses the opioid epidemic’s toll on children.

“It’s called overamping”: experiences of overdose among people who use methamphetamine” by University of Nevada, Reno, School of Public Health & University of New Mexico Health Sciences

The USA is experiencing increases in methamphetamine use and methamphetamine-related or attributed deaths. In the current study, we explore qualitative narratives of methamphetamine overdose and strategies used by people who use drugs to reduce the undesirable effects associated with methamphetamine use.

Factors Associated With Calling 911 for an Overdose: An Ethnographic Decision Tree Modeling Approach

Identification of Non-Fatal Opioid Overdose Cases Using 9-1-1 Computer Assisted Dispatch and Prehospital Patient Clinical Record Variables

Filter Magazine – Why New 12-Step Members May Avoid Carrying Naloxone by Jeanette Bowles, PhD, University of California San Diego, Division of Infectious Diseases and Global Public Health

For new members of 12-step programs like Alcoholics Anonymous and Narcotics Anonymous, naloxone can still seem like a symbol of drug use, according to new research. This can cause some people looking to kick drugs through these large abstinence-based fellowships—NA, for example, holds 70,000 weekly meetings in 144 countries, according to a 2018 survey—to decline to carry the overdose-reversal drug, seeing it as a relic of a past life.